Novel cosmetic or dermatological composition containing a strain of live probiotic bacteria

Abstract

The invention relates to a cosmetic or dermatological composition comprising at least one strain of live probiotic bacteria and at least one fat-dispersible and fat-soluble straight-chain molecule chosen from dicaprylyl carbonate, coco caprylate, coco caprate, undecane and / or tridecane, linoleic acid, behenyl alcohol or any one of the mixtures thereof, wherein the total content of the fat-dispersible and fat-soluble straight-chain molecules is at least 40% by weight with respect to the total weight of the composition. The invention also relates to the use of a fat-dispersible and fat-soluble straight-chain molecule chosen from dicaprylyl carbonate, coco caprylate, coco caprate, undecane and / or tridecane, linoleic acid, behenyl alcohol or any one of the mixtures thereof for maintaining the viability of a strain of live probiotic bacteria in a composition for topical administration.

Description

[0001] New cosmetic or dermatological composition containing a strain of live probiotic bacteria.

[0002] Technical field

[0003] The invention belongs to the field of dermatological or cosmetic compositions containing a strain of probiotic bacteria and at least 40% by weight of at least one liposoluble and lipodispersible molecule with a linear chain and their uses.

[0004] Technological background

[0005] It is recognized that probiotics are useful in topical application for the skin. Various clinical studies report the beneficial effects of probiotics on the skin in the cosmetic but also dermatological field. Probiotics are indeed of interest as a cosmetic ingredient (M. Rahmati Roudsari et al., Health effects of probiotics on the skin. Crit Rev Food Sci Nutr. 2015;55(9): 1219-40], The use of probiotics may also have great potential in the prevention and treatment of skin diseases, including eczema, atopic dermatitis, acne and allergic inflammation. Other applications are mentioned such as the treatment of skin hypersensitivity, UV-induced skin lesions and wound protection.

[0006] However, there are few probiotic products for topical applications available on the market due to technical difficulties related to the nature of this type of product. The main difficulty is to maintain the viability of the probiotic in the composition while preventing its proliferation, during the manufacturing but also storage of the composition. Indeed, most conventional cosmetic and / or dermatological formulations induce a loss of viability of the probiotic during manufacturing and / or storage, in particular due to the presence of compounds that are harmful or biocidal to bacteria. Conversely, in the absence of these compounds, particularly in aqueous formulations, the probiotic can proliferate, making its preservation impossible.

[0007] Furthermore, topical compositions must allow sufficient retention of the probiotic on the skin over time, which is not possible with conventional formulations [Garima Sharma, Manuhaar Sharma, Rishav Sood, Jayanthi Neelamraju, Suvama G. Lakshmi, Ratna Sudha Madempudi, Praveen Rishi & Indu Pal Kaur (2021) Self-preserving gelatin emulgel containing whole cell probiotic for topical use: preclinical safety, efficacy, and germination studies, Expert Opinion on Drug Delivery, 18: 11, 1777-1789], These difficulties thus hamper the use of probiotics by topical application, particularly in the cosmetic and dermatological fields.

[0008] The present invention therefore aims to solve this technical problem by providing a composition for supplementing the skin with probiotics by topical application in a safe, effective and practical manner while allowing the probiotic thus formulated to improve the health and / or beauty of the skin locally.

[0009] Solutions already exist in these areas but have drawbacks such as excessive formulation or application constraints, and are insufficient. Thus, solutions for application by microneedles, patches or encapsulation of probiotics have been described (WO2020127637A1; Hui-Jiuan Chen et al.. Transdermal Delivery of Living and Biofimctional Probiotics through Dissolvable Microneedle Patches. ACS Applied Bio Materials 2018 1 (2), 374-381)). Oily gels comprising an oil and an oily viscosity agent have also been described (WO2020 / 249734A1).

[0010] Summary of the invention

[0011] In this context and unexpectedly and surprisingly, the Applicant has discovered that a composition intended for topical application, in particular cosmetic and / or dermatological, containing at least 40% by weight of liposoluble and lipodispersible molecules with a linear chain, at least one of which is chosen from specifically selected liposoluble and lipodispersible molecules with a linear chain, optionally combined with one or more other liposoluble and lipodispersible molecules with a linear chain, makes it possible to solve this technical problem in a safe, simple, reliable, practical and effective manner.

[0012] The Applicant has in fact discovered that the use of one or more specifically selected liposoluble and lipodispersible linear chain molecules, optionally in combination with one or more other liposoluble and lipodispersible linear chain molecules, at a minimum total content of liposoluble and lipodispersible linear chain molecules of at least 40%, by weight relative to the total weight of a composition intended for topical application, such as a cosmetic and / or dermatological composition, makes it possible to maintain the viability of a live probiotic bacterium and thus resolve this technical problem.

[0013] The liposoluble and lipodispersible molecules with a linear chain specifically selected according to the invention are chosen from:

[0014] - dicaprylyl carbonate,

[0015] - coconut caprylate possibly combined with coconut caprate, preferably a mixture of coconut caprylate and coconut caprate,

[0016] - undecane and / or tridecane,

[0017] - linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol,

[0018] - behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters, and / or any of their mixtures.

[0019] Liposoluble and lipodispersible molecules with a linear chain are conventionally used in cosmetic and dermatological compositions for their emollient properties. However, it was not known that these molecules, and in particular those selected, when present at a minimum content of 40%, by weight relative to the total weight of the cosmetic and / or dermatological composition, made it possible to maintain the viability of live bacteria contained in this composition and thus to solve the problems of the prior art, unlike other liposoluble and lipodispersible molecules, in particular branched molecules, as described in the prior art. The examples show in fact that branched-chain fatty substances in the absence of the selected liposoluble and lipodispersible molecules with a linear chain do not make it possible to maintain the viability of the bacteria in a satisfactory manner.

[0020] The present invention thus makes it possible to develop cosmetic and dermatological compositions applicable topically which ensure in a particularly advantageous manner stability, in particular long-term viability of the probiotic without proliferation thereof for a satisfactory duration and compatible with the constraints of distribution and storage in the cosmetic and dermatological fields both for manufacturers and for users. Thus, in these compositions, the strain of probiotic bacteria is stable, that is to say that the strain remains alive and does not develop too much and therefore remains stable until its use.

[0021] As demonstrated in the examples, such compositions according to the invention remain stable, and in particular maintain the viability and therefore preserve the strain of probiotic bacteria that they advantageously contain for up to:

[0022] - at least 3 months at room temperature, i.e. at a temperature between 18 and 25°C, in particular around 21°C, and

[0023] -up to sixteen months, or even up to 18 months, at 4°C.

[0024] The liposoluble and lipodispersible molecules with linear chains used are oily or waxy in nature and thus make it possible to formulate probiotic bacteria strains in anhydrous formulations or those containing little water, thus avoiding the use of preservatives which destroy the probiotic bacteria strains by reducing their viability.

[0025] The compositions according to the invention are furthermore easy to apply and easily formulate unlike the solutions described in the prior art.

[0026] The subject of the invention is a cosmetic and / or dermatological composition comprising

[0027] - at least one strain of live probiotic bacteria,

[0028] - at least one lipodispersible and liposoluble molecule with a linear chain chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or their mixtures,

[0029] - and optionally one or more other lipodispersible and liposoluble molecules with a linear chain, in which the total content of lipodispersible and liposoluble molecules with a linear chain is at least 40% by weight relative to the total weight of the composition.

[0030] In particular, in the cosmetic and / or dermatological composition according to the invention, the other lipodispersible and liposoluble molecule with a linear chain is chosen from:

[0031] - Alkane molecules with chemical formula C n H2n+2 in which n denotes a value ranging from 6 to 40,

[0032] - Ester molecules with the chemical formula CEE- C'xlLx -COO- CyEEy- CEE in which each of x and y independently denotes a value ranging from 5 to 19,

[0033] - Acid molecules of chemical formula CEE- CxEEx -C(O)OH in which x denotes a value ranging from 5 to 24, preferably from 5 to 21, such as cerotic acid,

[0034] - Alcohol molecules with the chemical formula CEE-CxEEx-OH in which x denotes a value ranging from 5 to 21, and any of their mixtures.

[0035] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or their mixtures, is present at a content of at least 8%, preferably at least 10%, more preferably at least 15%, by weight relative to the total weight of the composition.

[0036] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble molecule with a linear chain is dicaprylyl carbonate.

[0037] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen is coconut caprylate optionally combined with coconut caprate, preferably a mixture of coconut caprylate and coconut caprate.

[0038] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen is dicaprylyl carbonate.

[0039] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen is undecane and / or tridecane.

[0040] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen is linoleic acid and / or oleic acid, and / or isostearyl linoleate and / or oleic alcohol, preferably linoleic acid.

[0041] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen is behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, or docosanoate or behenate esters, preferably behenyl alcohol or docosanol.

[0042] In particular, in the cosmetic and / or dermatological composition according to the invention, the lipodispersible and liposoluble linear chain molecule chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or their mixtures is present at a content of at least 40%, preferably at least 50%, more preferably at least 60%, by weight relative to the total weight of the composition.

[0043] In particular, the cosmetic and / or dermatological composition according to the invention comprises at least two molecules, preferably three or four, lipodispersible and liposoluble molecules with a linear chain chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters.

[0044] In particular, the cosmetic and / or dermatological composition according to the invention further comprises a liposoluble and lipodispersible branched chain molecule chosen from octyl dodecanol, propylheptyl caprylate, a mixture of caprylic and capric triglyceride, hydrogenated castor oil, shea butter, coconut oil and / or coconut glycerides.

[0045] In particular, in the cosmetic and / or dermatological composition according to the invention, the strain of live probiotic bacteria is chosen from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus, and mixtures thereof.

[0046] In particular, in the cosmetic and / or dermatological composition according to the invention, the live bacterial strain is formulated from powder obtained by freeze-drying on a maltodextrin support, preferably ranging from 10% to 80% by weight relative to the total weight of powder, preferably from 30% to 70%, more preferably from 40 to 60%, by weight relative to the total weight of powder.

[0047] In particular, in the cosmetic and / or dermatological composition according to the invention, the strain of live bacteria is at a content of 10 3 at 10 15 CFU (colony forming unit) per gram of composition.

[0048] In particular, in the cosmetic and / or dermatological composition according to the invention, the strain of live bacteria is at a content of 0.01 to 3% by weight, relative to the total weight of the composition.

[0049] In particular, in the cosmetic and / or dermatological composition according to the invention, the water activity (Aw) in the composition is less than 0.6.

[0050] In particular, the cosmetic and / or dermatological composition according to the invention is in the form of an oily suspension or solution, an oily cream or gel, a milk, a water-in-oil or multiple or silicone emulsion, a mask, a serum, a lotion, a solid soap, a shampoo in solid form, foaming products in solid form, a dermatological bar, an ointment, a mousse, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of makeup powders, sticks or sticks.The present invention further relates to the non-therapeutic use of a cosmetic composition according to the invention, for preventing and / or reducing unsightly and / or uncomfortable manifestations of healthy skin, healthy appendages and / or healthy mucous membranes, in particular sensitive or sensitized skin, appendages and / or mucous membranes, fragile or weakened skin, appendages and / or mucous membranes, and / or dry and / or atopic-prone skin, appendages and / or mucous membranes.

[0051] The present invention further relates to the non-therapeutic use of a cosmetic composition according to the invention, as a moisturizing and / or soothing agent for healthy skin, healthy appendages and / or healthy mucous membranes.

[0052] In particular, the non-therapeutic uses according to the invention are carried out by topical application, preferably on an area of ​​healthy skin, mucous membrane and / or appendage chosen from the legs; feet; armpits; hands; thighs; hips; buttocks; waist; crotch; groin; stomach; décolleté; neck; arms; torso; back; face including in particular the forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), external auditory canal and / or chin; scalp; hair; nails; and / or the labial mucosa, advantageously the armpits, décolleté, hair, nails, labial mucosa and / or the face, still advantageously the face.

[0053] The present invention further relates to the use of at least one lipodispersible and liposoluble linear chain molecule selected from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or their mixtures, and optionally one or more other lipodispersible and liposoluble linear chain molecules, for maintaining the viability of a live probiotic bacteria strain, wherein the total weight sum of the lipodispersible and liposoluble linear chain molecules is at least 40% by weight relative to the total weight of a cosmetic or dermatological composition.

[0054] The Applicant has also discovered that the compositions according to the invention containing at least one strain of live probiotic bacteria can thus be used as cosmetic compositions, in particular for improving the appearance and / or comfort of healthy skin, including healthy scalp and / or mucous membranes and / or healthy appendages, in particular hair and nails, and / or for the cosmetic care of healthy skin and / or mucous membranes and / or healthy appendages, including the most delicate skin such as sensitive, sensitized, fragile, weakened, dry skin, and / or healthy skin with atopic tendency. The selected liposoluble and lipodispersible linear chain molecules are emollients which also advantageously make it possible to improve the hydration of the skin and / or mucous membranes and / or to soften them.

[0055] The invention also relates to a cosmetic care method characterized in that it comprises the topical application to at least one area of ​​healthy skin and / or mucous membranes and / or healthy appendages of a cosmetic composition according to the invention, for the cosmetic treatment of sensitive healthy skin and / or healthy mucous membranes, sensitized healthy skin and / or healthy mucous membranes, fragile and / or weakened healthy skin and / or healthy mucous membranes, dry healthy skin and / or healthy mucous membranes, and healthy skin and / or healthy mucous membranes with an atopic tendency, and / or as a soothing agent or moisturizing agent.

[0056] The Applicant has also discovered that the compositions according to the invention, in particular dermatological compositions, are particularly suitable for the treatment and / or prevention of infections of the skin, mucous membranes and / or appendages caused by pathogenic microorganisms, in particular mycoses, S aureus such as eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by pathogenic bacteria such as S. aureus, and / or erythema, in particular infant diaper rash, and / or in the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies linked to reactive and / or atopic skin. These compositions according to the invention are therefore useful for the dermatological care of atopic and / or reactive skin and / or infant skin to prevent infant diaper rash.

[0057] The invention thus relates to a dermatological composition according to the invention, for its use as an anti-inflammatory, antibacterial and / or composition, in the treatment and / or prevention of infections of the skin and / or mucous membranes, in particular associated with a pathogenic microorganism such as a yeast or a bacterium, for example mycoses or S. aureus infections such as eczema, dandruff, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic bacterium such as S. aureus, and / or erythema, in particular diaper rash in infants, and / or in the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies linked to reactive and / or atopic skin.

[0058] In particular, the invention relates to a dermatological composition according to the invention, for use as an anti-inflammatory agent, an antibacterial agent and / or in the treatment and / or prevention of infections of the skin and / or mucous membranes and / or appendages induced by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S aureus, such as mycoses, eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S. aureus, a mycosis and / or erythema, in particular infant diaper rash, and / or in the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies linked to reactive and / or atopic skin and / or mucous membranes.

[0059] The invention also relates to a method for treating and / or preventing infections of the skin and / or mucous membranes, in particular associated with a pathogenic microorganism such as a yeast or a bacterium, for example mycoses or S. aureus infections such as eczema, dandruff, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic bacterium such as S. aureus, and / or erythema, in particular diaper rash in infants, and / or a method for preventing and / or treating pharmaceutically, in particular dermatologically, pathologies linked to reactive and / or atopic skin, in a patient in need thereof, comprising the administration of a pharmaceutically or dermatologically effective amount of a dermatological composition according to the invention, to said patient.

[0060] The invention also relates to the use of a dermatological composition according to the invention, for the preparation of an anti-inflammatory composition and / or an antibacterial composition and / or a medicament for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or appendages induced by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S aureus, such as mycoses, eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S. aureus, a mycosis and / or erythema, in particular infant diaper rash, and / or for the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies linked to reactive and / or atopic skin and / or mucous membranes.

[0061] The compositions according to the invention are advantageously intended for topical administration.

[0062] For the purposes of the present invention, the term "cosmetic use" and / or "cosmetic composition" means a non-pharmaceutical use and / or composition, i.e. one which is not intended for therapeutic use and is applied to a so-called healthy part of the body, in particular to a so-called healthy area of ​​skin.

[0063] For the purposes of the present invention, the term "healthy skin and / or mucous membrane" means an area of ​​human skin and / or mucous membrane to which the agent or composition according to the invention is applied and deemed "non-pathological" by a dermatologist, i.e. not presenting any infection, scar, disease or skin condition such as candidiasis, impetigo, psoriasis, eczema, inflammation, ichthyosis, acne or dermatitis, or wounds or injuries.

[0064] For the purposes of the present invention, the term "skin" means the skin of all or part of the body, in particular human, preferably chosen from the legs; feet; armpits; hands; thighs; hips; buttocks; waist; crotch; groin; stomach; décolleté; neck; arms; torso; back; face including the forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), external auditory canal and / or chin; and / or the scalp, more preferably chosen from the legs, feet, armpits, hands, thighs, stomach, décolleté, neck, arms, torso, back, face, and / or the scalp, advantageously the armpits, décolleté, face, and even more advantageously the face.

[0065] For the purposes of the present invention, the term "mucous membrane(s)" means the nasal, ocular, vaginal, urogenital and / or buccal mucosa, in particular the labial and / or gingival mucosa, preferably the urogenital and / or buccal mucosa, preferably the labial mucosa.

[0066] According to the present invention, the term "appendages" means hair fiber (hair), eyelashes, eyebrows, hair, in particular beard and / or moustache hair and / or nails, preferably nails and hair.

[0067] For the purposes of the present invention, the term "liposoluble and lipodispersible molecules" means molecules that are soluble and dispersible in a liquid oily phase, typically sunflower oil, at room temperature (i.e. between 18°C ​​and 25°C) or after heating between 60°C and 85°C, and at atmospheric pressure.

[0068] For the purposes of the present invention, the term "straight chain molecule" means an alkane, ester, acid, carbonate or alcohol molecule whose carbon chain(s) do not include any branching. The molecule thus comprises one or two straight carbon chains, i.e. a saturated or unsaturated carbon chain in which each carbon atom is covalently bonded to at most two other carbon atoms. It therefore does not contain any carbon group connected to the carbon chain(s).

[0069] For the purposes of the present invention, the term "branched chain molecule" means a molecule whose chain comprises at least one branch. The molecule thus comprises at least one branched carbon chain, i.e. a saturated or unsaturated carbon chain in which at least one of the carbon atoms is covalently bonded to at least three other carbon atoms. It may be saturated or unsaturated and contains at least one carbon group branched onto a carbon chain.

[0070] For the purposes of the present invention, the term “liposoluble and lipodispersible molecules with a linear chain” means the following molecules alone or in a mixture, preferably at least two of the molecules chosen from the following list:

[0071] - Alkane molecules with chemical formula C n H2n+2 in which n denotes a value ranging from 6 to 40;

[0072] - Ester molecules with the chemical formula CH3-C xH2x-C(O)OC y H2y-CH3 in which each of x and y independently denotes a value ranging from 5 to 19;

[0073] - Dicaprylyl carbonate;

[0074] - Acid molecules of chemical formula CH3- C'xl x -C(O)OH in which x denotes a value ranging from 5 to 24, preferably from 5 to 21; and

[0075] - Alcohol molecules with the chemical formula CLL-CxLLx-OH in which x denotes a value ranging from 5 to 21.

[0076] In particular, the liposoluble and lipodispersible molecules with a linear chain can be chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters; and / or their mixtures.

[0077] For the purposes of the present invention, the term "selected liposoluble and lipodispersible linear chain molecules" means the following molecules alone or in a mixture, preferably at least two of the molecules chosen from the following list: dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters (e.g., isostearyl linoleate) and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, otherwise known as docosanoic acid, or docosanoate or behenate esters; and / or their mixtures.

[0078] For the purposes of the present invention, the term “other lipodispersible and liposoluble molecules with a linear chain” means a lipodispersible and liposoluble molecule with a linear chain as defined above but different from the liposoluble and lipodispersible molecules with a linear chain selected as also defined above.

[0079] The term "derivatives" of an acid molecule according to the present invention means alcohol and ester derivatives. The term "derivatives" of an alcohol molecule according to the present invention means acid and ester derivatives.

[0080] For the purposes of the present invention, the term "maintaining viability" means preventing the increase and / or decrease in the number of colony-forming units (CFU) of a live strain of bacteria in the composition over time. The viability of a live strain of bacteria according to the invention is said to be maintained if the number of CFU counted after a given time varies by a maximum of 2 log, preferably by one log, more or less compared to the number of CFU initially counted during the formulation of the composition according to the invention.

[0081] The maintenance of viability is preferably evaluated after a determined time ranging from one month to twenty-four months, preferably one month, preferably 3 months, still preferably 6 months, still preferably 12 months and / or 16 months and / or 18 months from the formulation of the composition according to the invention.

[0082] The maintenance of viability is preferably evaluated after storage at a temperature between 0°C and 30°C, preferably between 2°C and 25°C, preferably between 2°C and 6°C and / or between 10°C and 30°C and preferably at room temperature (i.e. between 18°C ​​and 25°C, in particular approximately 21°C).

[0083] The number of CFU can be evaluated using conventional methods in this area, in particular by counting the strain of bacteria, in particular by taking a sample of a determined quantity of composition, placed in an appropriate culture medium, such as the method described in example 2.

[0084] For the purposes of the present invention, the term "maintaining the stability" of a composition comprising a strain of live bacteria means preventing the increase or decrease of the parameters conventionally defined in the field, such as for example organoleptic parameters such as color and / or odor and / or galenic formulation parameters such as pH, maintenance of phases, absence of precipitation of compounds and / or development of another strain of microorganisms.

[0085] The live bacterial strain used in the present invention is called probiotic. For the purposes of the present invention, the term "probiotic or probiotic bacterial strain" means one or more live, therefore viable, strains of bacteria, i.e. capable of forming colonies in culture. The so-called probiotic bacterial strains according to the invention are those of cosmetic and / or dermatological interest and which can be administered topically without risk to humans.

[0086] For the purposes of the present invention, the term "live probiotic bacterial strain" means a whole strain of bacteria known as viable, that is to say a strain of bacteria capable of forming colonies in culture.

[0087] For the purposes of the present invention, the term "physiologically acceptable excipient" means an excipient suitable for topical application, for cosmetic, pharmaceutical or dermatological use, which is non-toxic, non-irritating to the skin, does not induce an allergic response, and which is not chemically unstable.

[0088] “Topical administration or route” means the direct local application and / or spraying of the composition onto the surface of the skin, in particular the scalp and / or mucous membranes and / or appendages.Thus, the composition can be applied topically to all or part of the body and / or face, advantageously chosen from the legs; feet; armpits; hands; thighs; hips; buttocks; waist; crotch; groin; stomach; décolleté; neck; arms; torso; back; face including the forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), labial mucosa, external auditory canal and / or chin; hair; and / or the scalp, more preferably chosen from the legs, feet, armpits, hands, thighs, stomach, décolleté, neck, arms, torso, back, face, hair, nails and / or labial mucosa and / or the scalp, advantageously the décolleté, face, hair, nails and / or labial mucosa, still advantageously the face;armpits, décolleté, hair, nails, labial mucosa, scalp and / or face, very advantageously the face.

[0089] Due to the complementary emollient properties of the liposoluble and lipodispersible molecules selected according to the present invention, the cosmetic compositions according to the invention are particularly suitable for the care and / or cosmetic treatment of unsightly and / or uncomfortable manifestations of all types of skin, in particular so-called normal and / or dry skin and / or mucous membranes but also sensitive and / or sensitized and / or fragile and / or weakened and / or atopic-prone skin and / or dry skin and / or mucous membranes.

[0090] Generally speaking, "sensitive skin and / or mucous membranes" can be defined as healthy skin and / or healthy mucous membranes which, by nature, have very little tolerance for aggressive agents, particularly environmental agents such as pollutants, climatic factors (wind, cold, heat), UV exposure, emotional factors, particularly stress and / or chemical agents (heavy metals, detergents, compounds contained in cosmetic treatments such as perfumes, preservatives, alcohols, pH, AHA or dermatological agents such as vitamin A acid) and / or aggressive conditions, particularly perspiration and mechanical aggressions such as hair removal, shaving, rubbing and even water, particularly hard water. Sensitive skin is not pathological skin, unlike allergic skin.They may nevertheless react to aggressive agents and / or conditions with unsightly and / or uncomfortable cutaneous and / or mucosal manifestations such as cutaneous and / or mucosal dryness, a loss of homogeneity of the complexion of the skin and / or mucous membranes, in particular through the appearance of redness, sensations of tightness, tingling, prickling, tension and / or itching, a rough appearance of the skin and / or mucous membranes and / or a loss of softness to the touch. Thus, the "sensitive skin" character can be estimated by the subject himself with subjective cutaneous sensations or by the dermatologist with objective cutaneous reactions.

[0091] Unsightly and / or uncomfortable manifestations can be generalized to the whole body, but most of the time they can have well-defined locations such as for example the scalp, the face, skin folds, the buttocks in infants, etc. It can therefore be sensitive areas of skin and / or mucous membranes.

[0092] Similarly, “sensitized skin and / or mucous membranes” are healthy skin and / or healthy mucous membranes that have been made sensitive temporarily and are therefore not pathological as such.

[0093] "Fragile or weakened skin and / or mucous membrane (i.e., temporarily made fragile)" is healthy skin and / or mucous membrane whose barrier function is weakened. This condition may be linked to the individual's condition, and / or linked to age, with the elderly and infants having fragile skin, for example. This condition may also result from chemical or physical aggression (abrasion, friction, cuts).

[0094] Likewise, the dermatological compositions according to the invention are particularly suitable for the care and / or dermatological treatment of pathological skin and / or mucous membranes, in particular atopic and / or reactive skin and / or mucous membranes.

[0095] “Atopic-prone skin and / or mucosa” is healthy skin and / or mucosa that is extremely fragile and / or weakened, whose permeability is increased due to the weakened barrier function and which is genetically predisposed to evolve under the effect of multiple intrinsic and extrinsic factors towards a pathological state which is atopic dermatitis. Thus, the “atopic-prone skin” character can be estimated by the subject himself with subjective skin sensations or by the dermatologist with objective skin reactions.

[0096] The uncomfortable and / or unsightly manifestations of sensitized, fragile and / or weakened skin and / or mucous membranes are the same as for sensitive skin and / or mucous membranes, without these manifestations and / or skin conditions being related to the prevention and / or treatment of a pathology.

[0097] “Reactive skin and / or mucous membrane” otherwise known as intolerant or irritable or allergic is skin and / or mucous membrane whose tolerance threshold has decreased and which reacts excessively.

[0098] "Atopic skin and / or mucosa" is skin and / or mucosa affected by the pathology atopic dermatitis. The characteristics "reactive skin and / or mucosa" and "atopic skin and / or mucosa" can be estimated by the dermatologist with objective skin reactions.

[0099] In the context of the present invention, the cosmetic and / or dermatological composition comprises:

[0100] - at least one strain of live probiotic bacteria,

[0101] - at least one lipodispersible and liposoluble molecule with a selected linear chain,

[0102] - and optionally one or more other lipodispersible and liposoluble molecules with a linear chain, in which the total content of lipodispersible and liposoluble molecules with a linear chain is at least 40% by weight relative to the total weight of the composition.

[0103] The liposoluble and lipodispersible linear chain molecules selected according to the present invention are chosen from:

[0104] - dicaprylyl carbonate,

[0105] - coconut caprylate possibly combined with coconut caprate, preferably a mixture of coconut caprylate and coconut caprate,

[0106] - undecane and / or tridecane,

[0107] - Linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol,

[0108] - Behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters, and / or any of their mixtures.

[0109] Indeed, as demonstrated in example 2, the Applicant has found that these selected linear chain molecules make it possible to maintain the viability of the probiotic bacteria strain.

[0110] In particular, the liposoluble and lipodispersible linear chain molecules selected according to the invention are:

[0111] • Straight chain acids:

[0112] - Dicaprylyl carbonate: otherwise known as dioctyl carbonate, with the formula C17H34O3 and CAS number 1680-31-5; this molecule is a diester of carbonic acid and caprylyl alcohol. It is traditionally marketed by BASF under the name Cetiol® CC or contained in a mixture such as in the product Cosmedia® Gel CC marketed by BASF.

[0113] - Coco caprylate: INCI name Coco-Caprylate and otherwise known as coco alkyl ester of octanoic acid (CAS 107525-85-9); this linear fatty chain ester is traditionally marketed by BASF under the name Cetiol® C5.

[0114] - Coco caprylate can be combined with coco caprate, with the INCI name Coco-Caprylate / Caprate; this combination with the INCI name coco caprylate / caprate, and CAS number 95912-86, is traditionally marketed by BASF under the name Cetiol® C 5C.

[0115] These linear chain acids are known and used in cosmetic and dermatological compositions as emollients.

[0116] • Straight-chain alkanes:

[0117] - undecane: this is an alkane with the formula Cl 1H24 and CAS number 1120-21-4

[0118] - tridecane: this alkane with formula C13H28 and CAS number 629-50-5 is traditionally marketed by BASF under the name Cetiol® iSan

[0119] - a mixture of undecane and tridecane is traditionally marketed by BASF under the name Cetiol® Ultimate

[0120] • a linear chain fatty acid or its derivatives:

[0121] - linoleic acid: this is a polyunsaturated fatty acid from the omega 6 group. It may in particular be contained in a mixture rich in linoleic acid such as Argania spinosa seed oil marketed under the name Lipofructyl™ argan by the Applicant. Preferably, the linoleic acid is added in the form contained in a mixture rich in linoleic acid, i.e. containing at least 70% or in pure form.

[0122] - Oleic acid: this is a monounsaturated fatty acid from the omega 9 group. It can in particular be contained in a mixture rich in linoleic acid, i.e. containing at least 50%, preferably at least 70%, such as in the form of a rapeseed oil rich in omega 9 such as that marketed under the name Cegesoft PS6 marketed by BASF-

[0123] - Linear chain esters of linoleic acid or oleic acid are linear chain molecules comprising a chain group of up to 20 carbons esterified on the acid function, such as isostearyl linoleate or decyl oleate.

[0124] - Oleic alcohol

[0125] • a linear chain fatty alcohol:

[0126] - Behenyl alcohol: it is also known as docosanol and has the formula C22H46O - it is traditionally marketed by BASF under the name Lanete® 22. Its acid and ester derivatives are in particular chosen from behenic acid, also known as docosanoic acid, its docosanoate or behenate esters and / or their mixtures.

[0127] Advantageously, the selected liposoluble and lipodispersible linear chain molecule(s) are contained in the cosmetic or dermatological composition at a minimum content of 8%, more preferably at least 10%, more preferably at least 15%, more preferably 40%, more preferably at least 50% by weight, advantageously at least 60% by weight, more preferably 70% by weight relative to the total weight of the composition. The cosmetic or dermatological composition according to the invention advantageously comprises a mixture of at least two, more preferably three or four of the selected liposoluble and lipodispersible linear chain molecules, provided that the total content of liposoluble and lipodispersible linear chain molecules is at least 40%, more preferably at least 50%, more preferably at least 60% by weight relative to the total weight of the cosmetic or dermatological composition.

[0128] According to one embodiment, the selected liposoluble and lipodispersible linear chain molecules are used as purified molecules or contained in mixtures containing them such as extracts. In particular, they are used as purified molecules.

[0129] The liposoluble and lipodispersible molecules with a linear chain selected according to the invention may be combined with other liposoluble and lipodispersible molecules with a linear chain which are not selected provided that the total content of liposoluble and lipodispersible molecules with a linear chain is at least 40%, preferably at least 50%, even more preferably at least 60% by weight relative to the total weight of the cosmetic or dermatological composition.

[0130] These other liposoluble and lipodispersible molecules with a linear chain which may be contained in the composition in association with those selected are preferentially chosen from:

[0131] Alkane molecules with the chemical formula C n H2n+2 in which n denotes a value ranging from 6 to 40, preferably one of the paraffins for which n is between 8 and 40, advantageously between 20 and 40 or between 8 and 19, such as for example dodecane, tetradecane and / or pentadecane;

[0132] Ester molecules of chemical formula CH3- C'xlLx -COO- CL - CH3 in which each of x and y independently denotes a value ranging from 3 to 19 such as myristyl myristate C28H56O2, cetearyl palmitate, cetyl palmitate, butyl palmitate, myricyl palmitate;

[0133] Acid molecules with the chemical formula CH3-C x H 2x-C(O)OH in which x denotes a value ranging from 5 to 24, preferably from 5 to 21, such as cerotic acid;

[0134] Alcohol molecules with the chemical formula CH3-C x H 2x -OH in which x denotes a value ranging from 5 to 21; and any mixture thereof.

[0135] According to a preferred embodiment, the present invention relates to a composition intended for topical application, in particular a cosmetic or dermatological composition, comprising at least one strain of live probiotic bacteria and at least 40%, by weight relative to the total weight of the composition, of one or more selected liposoluble and lipodispersible linear chain molecules, preferably at least two selected liposoluble and lipodispersible linear chain molecules.

[0136] Advantageously, the composition according to the invention does not contain paraffin or glycerin.

[0137] The cosmetic or dermatological composition according to the invention advantageously comprises a mixture of at least two, preferably three or four of the selected liposoluble and lipodispersible linear chain molecules, the sum of which is at least 40% by weight, preferably 50% by weight relative to the total weight of the cosmetic or dermatological composition.

[0138] According to a particular embodiment of the invention, the liposoluble and lipodispersible molecules with a linear chain included in the cosmetic or dermatological composition are chosen solely from the liposoluble and lipodispersible molecules with a selected linear chain. In other words, the cosmetic or dermatological composition according to the invention is free of liposoluble and lipodispersible molecules with a linear chain other than those selected.

[0139] According to a particular embodiment of the invention, the cosmetic or dermatological composition is made up of one or more selected liposoluble and lipodispersible linear chain molecules and a strain of live probiotic bacteria.

[0140] The compositions according to the invention contain at least one strain of live probiotic bacteria. According to the invention, the term "live probiotic bacteria strain" means a strain of bacteria of cosmetic and / or dermatological interest, i.e. non-pathogenic and whose topical application can improve the aesthetics and / or comfort of healthy skin or treat pathologies. These may be wild or genetically modified bacteria.

[0141] Preferably, these are the following bacteria:

[0142] From the group of lactic bacteria, in particular Lactobacillus rhamnosus, brevis, crispatus, delbrueckii, fermentum, helveticus, plantarum, iners, gasserjensenii, reuteri, brevis and / or acidophilus, preferably Lactobacillus crispatus

[0143] From the group of Cocci, in particular Alloicoccus otitis, Lactococcus lactis, Streptococcus thermophilus, Streptococcus salivarius, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus warneri, Staphylococcus caprae, and / or Staphylococcus saprophyticus;

[0144] Du groupe des Micrococcus notably Micrococcus luteus;

[0145] Du groupe des Bifidobacteries, notably Bifidobacterium longum and / or Bifidobacterium infantis;

[0146] Du groupe des Corynebacterium, notably Corynebacterium accolens; Corynebacterium tuberculostearicum, and / or Corynebacterium amycolatum; Du Groupe des Sphingomonas, notably Sphingomonas glacialis;

[0147] From the Bacillus group, notably Bacillus cereus (subtilis), and / or Bacillus licheniformis; and From the Cutibacterium group, notably Cutibacterium acnes.

[0148] More preferably, these are the following bacteria:

[0149] From the group of lactic acid bacteria, in particular Lactobacillus rhamnosus, brevis, crispatus, delbrueckii, fermentum, helveticus, plantarum, iners, gasserijensenii, reuteri, brevis and / or. acidophilus, preferably Lactobacillus crispatus

[0150] From the Cocci group, in particular Alloicoccus otitis, Lactococcus lactis, Streptococcus thermophilus, Streptococcus salivarius, Staphylococcus epidermidis, and / or Staphylococcus hominis;

[0151] From the group of Bifidobacteria, notably Bifidobacterium longum, and / or Bifidobacterium infantis;

[0152] From the Corynebacterium group, notably Corynebacterium accolens;

[0153] From the Sphingomonas Group, notably Sphingomonas glacialis;

[0154] From the Bacillus group, notably Bacillus cereus (subtilis), and / or Bacillus licheniformis; From the Cutibacterium group, notably Cutibacterium acnes.

[0155] Preferably, the strain of live probiotic bacteria is chosen from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus and their mixtures.

[0156] Particularly advantageously, the live probiotic bacteria strain is one of the following strains deposited under the Budapest Treaty with the Pasteur Institute (25 rue du Docteur Roux, F-75724 Paris cedex 15):

[0157] - the strain of Lactobacillus crispatus deposited under number CNCM 1-5579

[0158] - the strain of Sphingomonas glacialis deposited under number CNCM 1-5829.

[0159] The live probiotic bacteria strain can be formulated in powder form, i.e., in dry form, or in suspension form.

[0160] Generally speaking, the live probiotic bacteria strain can be isolated before its composition, i.e. not mixed with one or more compounds from its original medium. Alternatively, the live probiotic bacteria strain can be combined with compounds from its original medium, in particular its culture medium.

[0161] According to a preferred embodiment, the live probiotic bacteria strain may be combined with a bacteria strain in inactivated form, in particular in dead form and / or in the form of its lysate, and / or in the form of one or more of its fractions and / or in the form of one or more of its metabolites, in particular its secretome. It may thus be the same bacteria strain in inactivated form or another bacteria strain in inactivated form. Preferably, it will be the same bacteria strain as the live probiotic bacteria strain.

[0162] According to one embodiment, the compositions according to the invention may contain several strains of live probiotic bacteria or a strain of live probiotic bacteria combined with another strain of bacteria in inactivated form, in particular in dead form and / or in the form of its lysate, and / or in the form of one or more of its fractions and / or in the form of one or more of its metabolites, in particular its secretome.

[0163] Particularly advantageously, the live probiotic bacteria strain is contained in the cosmetic or dermatological composition, at a concentration of 0.001 to 3% (w / w) by weight, more preferably at a concentration of 0.01 to 0.3% (w / w) of approximately 0.025% (w / w) by weight, relative to the total weight of the composition.

[0164] Advantageously, the live probiotic bacteria strain is contained in the cosmetic or dermatological composition, at a concentration per gram of composition ranging from 10 3 colony forming units (CFU) at 10 15 CFU / g, preferably ranging from 10 4 at 10 10 UFC / g still preferably ranging from 10 5 at 10 9 UFC / g, still preferably ranging from 10 5 at 10 8 CFU / g, still preferably around 10 5 CFU / g.

[0165] Advantageously, the live probiotic bacteria strain is contained in the cosmetic composition, at a concentration per gram of composition ranging from 10 3 at 10 8 UFC / g still preferably ranging from 10 4 at 10 8 UFC / g, still preferably ranging from 10 5 at 10 8 CFU / g, still preferably around 10 5 CFU / g.

[0166] Advantageously, the live probiotic bacteria strain is contained in the dermatological composition, at a concentration per gram of composition ranging from 10 9 colony forming units (CFU) at 10 15 CFU / g, preferably ranging from 10 9 at 10 13 CFU / g.

[0167] The production of the live probiotic bacteria strain may be carried out according to any method conventionally known to those skilled in the art. Advantageously, it will be carried out according to the protocol as described for example in Example 1.

[0168] According to an advantageous embodiment, the cosmetic or dermatological composition according to the invention has a water activity of less than 0.6, even more preferably less than 0.5, even more preferably less than 0.4. The water activity (known as AW for activity water) indicates the availability of so-called "free" water in a matrix. It is therefore not the exact water content of a medium, but only the water likely to be involved in chemical, biochemical or microbiological reactions. It is defined in relation to a reference state which is pure water, therefore without any solute. The value of AW varies between 0 and 1. It is equal to 0 when the product is dry and all the water is bound to the matrix (without reactive quality). It is equal to 1 in the case of pure water.

[0169] Water activity is measured in a manner conventionally accepted by those skilled in the art with a water activity measuring device, such as the Aqualab devices marketed by the company Metergroup.

[0170] According to a further preferred embodiment, the composition according to the invention contains a maximum of 5% by weight of added water relative to the total weight of the composition, preferably less than 3% and even more preferably does not contain any added water. According to a particular embodiment, the composition according to the invention is a non-aqueous composition.

[0171] According to a particular embodiment of the invention, the live probiotic bacteria strain is included in an oily phase (or non-aqueous phase). Alternatively, the live probiotic bacteria strain according to the invention can be used dispersed and / or diluted in a solvent. Preferably, this solvent contains less than 20% (v / v) by volume of water, more preferably less than 5% (v / v) by volume of water, more preferably the solvent does not contain water.

[0172] According to a preferred embodiment, this solvent contains less than 20% (w / w) by weight of water, even more preferably less than 5% (w / w) by weight of water, even more preferably the solvent does not contain water. Very preferably, this solvent is one of the liposoluble and lipodispersible molecules selected according to the invention.

[0173] The live probiotic bacteria strain according to the invention is added to the composition according to the invention preferably in dry form, that is to say in powder form, advantageously in maltodextrin, preferably in a strain content of 10% to 80% (w / w) by weight of the strain, preferably 30% to 70% (w / w), still advantageously 40 to 60% (w / w) by weight of the strain relative to the total weight of powder.

[0174] According to a particular embodiment, the cosmetic or dermatological composition according to the present invention in its embodiment may comprise:

[0175] - at least one strain of live probiotic bacteria chosen from Lactobacillus crispatus, Corynebacterium accolens and Sphingomonas glacialis, Streptococcus salivarus and their mixtures, preferably the strain of Lactobacillus crispatus deposited under number CNCM 1-5579 and Sphingomonas glacialis, preferably the strain deposited under number CNCM 1-5829;

[0176] - said strain of live probiotic bacteria being preferably:

[0177] ° at a content ranging from 10 4 at 10 10 UFC / g still preferably ranging from 10 5 at 10 9 UFC / g, still preferably ranging from 10 5 at 10 8 CFU / g of the composition,

[0178] ° added to the composition in the form of lyophilized powder on a maltodextrin support at a strain content ranging from 40 to 60% (w / w) by weight of the strain relative to the total weight of maltodextrin powder;

[0179] - at least one liposoluble and lipodispersible molecule with a linear chain chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters; and any of their mixtures;

[0180] - at least one other liposoluble and lipodispersible molecule with a linear chain; and

[0181] - a total content of liposoluble and lipodispersible molecule with a linear chain of at least 40%, preferably 50% by weight relative to the total weight of the composition.

[0182] The cosmetic or dermatological composition according to the present invention in its preferred embodiment comprises:

[0183] - at least one strain of live probiotic bacteria chosen from Lactobacillus crispatus, Corynebacterium accolens and Sphingomonas glacialis, Streptococcus salivarus and their mixtures, preferably the strain of Lactobacillus crispatus deposited under number CNCM 1-5579 and Sphingomonas glacialis, preferably the strain deposited under number CNCM 1-5829;

[0184] - said strain of live probiotic bacteria being preferably:

[0185] ° at a content ranging from 10 4 at 10 10 UFC / g still preferably ranging from 10 5 at 10 9 UFC / g, still preferably ranging from 10 5 at 10 8 CFU / g of the composition,

[0186] ° added to the composition in the form of lyophilized powder on a maltodextrin support at a strain content ranging from 40 to 60% (w / w) by weight of the strain relative to the total weight of maltodextrin powder;

[0187] - at least one, preferably at least two, liposoluble and lipodispersible molecules with a linear chain chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters; and any of their mixtures;

[0188] - a total content of liposoluble and lipodispersible molecule with a selected linear chain of at least 40%, preferably 50% by weight relative to the total weight of the composition.

[0189] Cosmetic and dermatological compositions are made using classic formulation methods.

[0190] Preferably, the live probiotic bacteria strain is dispersed preferentially directly in the liposoluble and lipodispersible molecules with a linear and / or branched chain, preferentially those with a linear chain, even more preferentially those with a selected linear chain, i.e. chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferentially a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters; and any of their mixtures.

[0191] Preferably, the composition according to the invention is produced at a maximum temperature of 70°C in the context of so-called hot manufacturing or at room temperature, i.e. between 18°C ​​and 25°C, in particular approximately 21°C, in the context of so-called cold manufacturing.

[0192] Advantageously, the manufacturing temperature does not exceed 70°C for a maximum duration of 3 hours. It will be adjusted according to the resistance of the strain of live bacteria concerned.

[0193] In a preferred embodiment, the composition according to the invention will be produced at room temperature, i.e. between 18°C ​​and 25°C, in particular 21°C, in the context of so-called cold manufacturing.

[0194] The cosmetic and dermatological composition according to the invention is a composition for topical administration.

[0195] In an advantageous embodiment, the composition according to the invention further comprises a physiologically acceptable excipient, in particular cosmetically, pharmaceutically or dermatologically acceptable.

[0196] In the context of the invention, the live probiotic bacteria strain is used as an active agent in the composition, in particular as a cosmetic or dermatological active ingredient to prevent and / or reduce the unsightly and / or uncomfortable manifestations of healthy skin and / or healthy mucous membranes known as normal, sensitive and / or sensitized and / or fragile and / or weakened and / or dry and / or with atopic tendency.

[0197] The cosmetic or dermatological composition according to the invention may also be used in the form of a cosmetic or dermatological agent or a premix intended to be incorporated into another cosmetic or dermatological composition, and further comprising a suitable cosmetic or pharmaceutical excipient, in particular just before its immediate application.

[0198] In this case, according to a particularly advantageous mode for this mode of administration, the strain of live probiotic bacteria is then contained in the composition according to the invention at a more concentrated dose, in particular at a concentration ranging from 0.001 to 3% by weight, still preferably at a concentration of 0.01 to 0.3% by weight, still preferably from 0.1% to 0.25% still preferably at a concentration of approximately 0.20% by weight relative to the total weight of the composition.

[0199] Preferably, the composition according to the invention is a ready-to-use cosmetic or dermatological composition, i.e. one that can be used directly by topical application.

[0200] The composition according to the invention does not comprise an agent at a biocidal and / or preservative dose which may alter the viability of the live probiotic strain.

[0201] The compositions according to the invention may contain any suitable solvent, excipient, vehicle, as well as other active ingredients, provided that this does not alter the stability of the composition, in particular the viability of the live probiotic bacteria strain.

[0202] Advantageously, the composition according to the invention may also contain liposoluble and lipodispersible molecules with a non-linear chain, in particular branched-chain fatty substances, provided that the liposoluble and lipodispersible molecule(s) with a linear chain, in particular those selected, are present in the cosmetic composition at a minimum content of 40%, preferably at least 50% by weight, still advantageously at least 60% by weight, still preferentially at least 70% by weight relative to the total weight of the composition.

[0203] Branched-chain fatty substances are generally understood to mean liquid, pasty or solid oily compounds, in particular waxes, with a branched chain, in particular vegetable oil, as well as saturated fatty acids with one or more hydrocarbon branches on the carbon chain (classically called BCFA (branched chain fatty acid)). These branched-chain fatty substances are commonly used in many cosmetic and dermatological compositions as texturizing agents, emollients, structuring agents, and rheology-modifying agents.

[0204] The branched-chain fatty body(ies) are advantageously those chosen from fatty body type oils with a branched chain such as:

[0205] - octyldodecanol, otherwise known as Eutanol® G;

[0206] - propylheptyl caprylate, notably marketed by BASF under the name Cetiol® Sensoft;

[0207] - a mixture of caprylic and capric triglyceride known under the number CAS73398-61-5 such as that marketed by BASF under the name Myritol® 318;

[0208] - hydrogenated castor oil;

[0209] - shea butter or other fatty acids, such as the mixture marketed by BASF under the name Cetiol® SB 45 comprising oleic, stearic, linolenic, palmitic, linoleic and arachidonic acids;

[0210] - coconut oil and / or coconut glycerides, in particular those marketed by BASF under the name Myritol®331;

[0211] - squalane or squalane derivatives such as hemisqualane.

[0212] Preferably, the composition according to the invention contains a maximum quantity of 40%, preferably 30% by weight of branched-chain fatty substances, in particular those listed above, even more preferably less than 20% by weight relative to the total weight of the composition. Indeed, according to this preferred embodiment, the composition has improved viability at room temperature, as demonstrated in example 6.

[0213] According to a particular embodiment of the invention, the cosmetic or dermatological composition is free of liposoluble and lipodispersible molecules with a non-linear chain, and therefore of fatty substances with a branched chain.

[0214] Other fat-soluble ingredients may be contained in the compositions according to the invention, such as for example:

[0215] - vitamins or antioxidants, in particular vitamin E, otherwise known as tocopherol, to prevent the oxidation of fatty substances;

[0216] - touch agents such as microcrystalline celluloses;

[0217] - texturizing agents such as thickeners and / or fatty phase gelling agents such as stearalkonium hectorite and propylene carbonate, notably marketed in the form of the Cosmedia ® Gel CC mixture marketed by BASF in association with dicaprylyl carbonate;

[0218] - other emollients.

[0219] The excipient(s) may thus be chosen from surfactants and / or emulsifiers, buffering agents, chelating agents, denaturants, opacifying agents, pH adjusters, reducing agents, stabilizing agents, thickeners, gelling agents, film-forming polymers, fillers, matting agents, glossing agents, pigments, colorants, perfumes, and mixtures thereof. The CTFA (Cosmetic Ingredient Handbook, 2016 Edition) describes various cosmetic excipients suitable for use in the present invention.

[0220] Advantageously, the excipient(s) are chosen from the group comprising polyglycerols, esters, cellulose polymers and derivatives, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, sucrose-based stabilizers, vitamin E and its derivatives, xanthan gums, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, silicones, protein hydrolysates, betaines, aminoxides, plant extracts, sucrose esters, titanium dioxides, glycines, and more preferably from the group consisting of steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, butylene glycol, caprylyl glycol, tocopherols. natural, glycerin, dihydroxycetyl sodium phosphate, isopropyl hydroxycetyl ether, glycol stearate, triisononanoin, octyl cocoate, polyacrylamide, isoparaffin, laureth-7,carbomer, propylene glycol, hexylene glycol, glycerol, bisabolol, dimethicone, sodium hydroxide, PEG 30-dipolyhydroxysterate, capric / caprylic triglycerides, cetearyl octanoate, dibutyl adipate, grape seed oil, jojoba oil, magnesium sulfate, EDTA, cyclomethicone, xanthan gum, citric acid, sodium lauryl sulfate, mineral waxes and oils, isostearyl isostearate, propylene glycol dipelargonate, propylene glycol isostearate, PEG 8, beeswax, hydrogenated palm kernel oil glycerides, lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, titanium dioxide, lactose, sucrose, and mixtures thereof.,

[0221] According to a particularly advantageous embodiment, the composition according to the invention also comprises biodegradable polymers chosen from:

[0222] - alginic acid, its salts and its topically acceptable esterified derivatives, advantageously chosen from ammonium alginate, sodium alginate, calcium alginate, magnesium alginate, sodium alginate sulfate and potassium alginate, glyceryl alginate or propylene glycol alginate, or mixtures thereof, advantageously sodium alginate and / or propylene glycol alginate;

[0223] - hyaluronic acid, its salts and its topically acceptable esterified derivatives, advantageously chosen from hydrolyzed calcium hyaluronate, hydrolyzed sodium hyaluronate, potassium hyaluronate, sodium hyaluronate, sodium sulfated hyaluronate, preferentially sodium hyaluronate;

[0224] - scleroglucan; and / or any of their mixtures.

[0225] According to a preferred embodiment of the present invention, it has been discovered that such polymers further increase the viability of the live probiotic bacteria strain in the composition according to the invention, in particular when they are present at a content of between 0.1% and 10%, more preferably between 1% and 5% by weight relative to the total weight of the cosmetic or dermatological composition.

[0226] The cosmetic or dermatological composition according to the invention may be chosen from an oily suspension or solution, an oily cream or gel, a milk, a water-in-oil or multiple or silicone emulsion, a mask, a serum, a lotion, a solid soap, a shampoo in solid form, foaming products in solid form, a dermatological bar, an ointment, a mousse, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of makeup powders, sticks or sticks.

[0227] Advantageously, the cosmetic or dermatological composition according to the invention is not in the form of a water-in-oil emulsion.

[0228] The cosmetic or dermatological composition may further comprise a cosmetically or dermatologically acceptable excipient chosen from surfactants, buffering agents, bulking agents, chelating agents, denaturants, opacifying agents, pH adjusters, reducing agents, stabilizing agents, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, odor absorbers, matting agents, conditioning agents, texturizing agents, shine agents, pigments, colorants, perfumes and chemical or mineral sunscreens, trace elements, essential oils. These combinations are also covered by the present invention.

[0229] The cosmetic or dermatological composition may contain other liposoluble and lipodispersible active ingredients.

[0230] The cosmetic or dermatological composition may also comprise other active ingredients for the treatment of normal skin and / or mucous membranes, sensitive, sensitized, reactive, fragile and / or weakened skin and / or mucous membranes and / or having an effect on the increase and / or protection and / or maintenance of the beneficial commensal flora at the level of the skin and / or mucous membranes, inducing a complementary or synergistic effect with the strain of probiotic bacteria according to the invention, chosen for example from

[0231] - a combination of sodium hyaluronate, pullulan and sodium alginate, notably marketed in a formulation containing serine, trehalose, urea and glycerin under the name PatcH2O™ or a combination of hyaluronic acid, pullulan and propylene glycol alginate with lactic acid, succinic acid and / or sucrose;

[0232] - other cosmetic ingredients intended for the care of sensitive skin such as a plant extract of Cestrum latifolium as described in application WO2009 / 112590 for example marketed under the name Symbiocell ™ by the applicant, a butter extracted from the fruit of the Irvingia gabonensis tree marketed under the name Irwinol ™ by the applicant, an extract of Eperua falcata root marketed under the name Eperuline ™, a peptide N-acetyl-L-Tyrosyl-L-Prolyl-L-Phenylalanyl- L-Phenylalaninamide (INCI: acetyl tetrapeptide 15) sold under the name Skinasensyl ™ by the applicant.

[0233] The cosmetic composition may also contain one or more ingredients active on the cutaneous and / or mucosal microbial flora and / or active on the barrier function of the skin, in particular moisturizing and / or soothing active ingredients, including an oligosaccharide obtained by enzymatic synthesis marketed by the company Solabia under the name BioEcolia™ or a complex of alpha-glucoligosaccharides marketed by the same company under the name Ecoskin™, an extract of Alisma plantago-aquatica, an extract of Argania spinosa (Lipofructyl™ Argan / , a mixture of ceramides (Sphingoceryl™ VEG), purifying extracts of Boldo (Betapur™), products based on inulin or fructooligosaccharides, extracts of bifidobacteria or an extract of Orthosiphon stamineus to combat oily skin (MAT-XS™ Bright), a natural extract of honey marketed by the applicant under the name Melhydran™ for its moisturizing property,a flax extract marketed under the name Oligolin™ by the applicant, an extract of Cassia angustifolia seeds and marketed by the applicant under the name Hyalurosmooth®, a biotechnologically modified yeast extract marketed by the applicant under the name Relipidium™, Hydagen GG a Pueraria lobata root extract marketed under the name Inhipase™ by the applicant, a beta-glucan derivative from baker's yeast marketed by Mibelle under the name CM-Glucan Forte™ and / or an extract of Mirabilis jalapa marketed under the name Pacifeel™ by Sederma, inulin, N-methylglycine as a skin prebiotic marketed in particular under the name Scalposine™ by the applicant, a barrier function repair agent extracted from phytosterols of Brassica campestris seed oil marketed by the applicant under the name Phytosoothe™,a moisturizing and soothing agent containing beta-glucans and marketed under the name Hydrasensyl glucan™ by the Applicant, a moisturizing agent comprising hyaluronic acid and konjac polysaccharides marketed under the name Ultra Filling Sphères™, an antioxidant, anti-inflammatory, anti-redness agent containing an extract of Inonotus obliquus marketed by the Applicant under the name Inolixir™ soothing, a protective agent against the effects of pollution, in particular an extract of Moringa oleifera seeds marketed by the Applicant under the name Purisoft™, an extract of Cassia angustifoloia marketed by the Applicant under the name Hyalurosmooth®, a soy extract fermented by a lactobacillus marketed by the Applicant under the name Phytofim™ biotic.,

[0234] According to a particularly advantageous embodiment, the active ingredient which is contained in the composition is of an oily and / or lipodispersible nature, such as an oily extract of Cyperus esculentus, marketed by the Applicant under the name Lypofructyl® cyperus, an extract of Argania spinosa fruit marketed by the Applicant under the name Argassential™, an extract of Schisandra chinensis fruit. dehydrated hyaluronic acid oily spheres marketed under the name Hyaluronic Filling Spheres.

[0235] Particularly advantageously, the cosmetic or dermatological composition according to the invention also comprises an extract of the fermentation medium of the strain of probiotic bacteria.

[0236] The present invention also relates to the use of at least one liposoluble and lipodispersible molecule with a linear chain chosen from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear chain esters (e.g. isostearyl linoleate) and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid otherwise known as docosanoic acid, or docosanoate or behenate esters; or any of their mixtures, for maintaining the viability of a live probiotic bacteria strain in a cosmetic or dermatological composition according to the invention, in which said molecule or its mixture is present at a content of at least 40% by weight relative to the total weight of the composition.

[0237] This use is particularly interesting and advantageous in the presence of a cosmetic or dermatological excipient, in particular when the composition contains one or more branched-chain fatty substances, in particular those previously defined, in particular when these have a content greater than 10%, preferably 20% by weight relative to the total weight of the composition and preferably between 20% and 40% by weight relative to the total weight of the composition.

[0238] The present invention also relates to the non-therapeutic cosmetic use by topical route of a cosmetic composition according to the invention, for the cosmetic treatment of healthy skin and / or healthy appendages and / or normal healthy mucous membranes, sensitive healthy skin and / or healthy appendages and / or healthy mucous membranes, sensitized healthy skin and / or healthy appendages and / or healthy mucous membranes, fragile healthy skin and / or healthy appendages and / or healthy mucous membranes, healthy dry skin and / or healthy appendages and / or mucous membranes, and / or healthy skin and / or healthy mucous membranes with atopic tendency.

[0239] The invention further relates to a cosmetic care method characterized in that it comprises the topical application to at least one area of ​​healthy skin and / or healthy mucous membranes, of a cosmetic composition according to the invention, for the cosmetic treatment of normal healthy skin and / or healthy appendages and / or healthy mucous membranes, sensitive healthy skin and / or healthy appendages and / or healthy mucous membranes, sensitized healthy skin and / or healthy appendages and / or healthy mucous membranes, fragile and / or weakened healthy skin and / or healthy appendages and / or healthy mucous membranes, dry healthy skin and / or healthy appendages and / or healthy mucous membranes, and healthy skin and / or healthy mucous membranes with atopic tendency.

[0240] In an advantageous embodiment of the invention, the cosmetic care method comprises the topical application of the cosmetic composition according to the invention to all or part of the body and / or the face, advantageously chosen from the legs; feet; armpits; hands; thighs; hips; buttocks; waist; crotch; groin; stomach; décolleté; neck; arms; torso; back; face including the forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), labial mucosa, external auditory canal and / or chin; hair;and / or the scalp, more preferably chosen from the legs, feet, armpits, hands, thighs, stomach, décolleté, neck, arms, torso, back, face, hair, nails and / or labial mucosa and / or scalp, advantageously the décolleté, face, hair, nails and / or labial mucosa, still advantageously the face; the armpits, décolleté, hair, nails, labial mucosa, scalp and / or face, very advantageously the face.;

[0241] In one embodiment, the amount of live probiotic bacteria strain contained in the cosmetic composition does not provide a therapeutic effect.

[0242] Advantageously, the invention also relates to a cosmetic (non-therapeutic) treatment method for preventing and / or reducing the unsightly and / or uncomfortable manifestations of healthy skin and / or healthy appendages and / or healthy sensitive and / or sensitized and / or fragile and / or weakened and / or dry and / or atopic-prone mucous membranes of an individual who needs / wants it, comprising the steps: a) Identifying on the individual an area of ​​healthy skin and / or mucous membrane and / or appendages for which it is desired to prevent and / or reduce the unsightly and / or uncomfortable manifestations and / or for which it is desired to prevent and / or reduce the sensitivity and / or fragility and / or dryness and / or atopic tendency,and b) The topical application to this area of ​​healthy skin and / or healthy appendages and / or healthy mucous membrane of a cosmetic composition according to the invention in an effective amount to prevent and / or reduce unsightly and / or uncomfortable manifestations on this area of ​​skin, appendages and / or mucous membrane and / or in an effective amount to prevent and / or reduce its sensitivity and / or its fragility and / or its dryness and / or its atopic tendency.,

[0243] The invention further relates to a dermatological composition as defined above, optionally with a cosmetically and / or dermatologically acceptable excipient.

[0244] The cosmetically and / or dermatologically acceptable excipient(s) may be chosen from surfactants and / or emulsifiers, buffering agents, chelating agents, denaturants, opacifying agents, pH adjusters, reducing agents, stabilizing agents, thickeners, gelling agents, film-forming polymers, fillers, matting agents, glossing agents, pigments, colorants, perfumes, and mixtures thereof. The CTFA (Cosmetic Ingredient Handbook, 2016 Edition) describes various cosmetic excipients suitable for use in the present invention. A person skilled in the art knows how to adapt the formulation of the composition according to the invention using his general knowledge.

[0245] The invention further relates to a dermatological composition according to the invention, as defined above, for its use as an anti-inflammatory agent, an antibacterial agent and / or in the treatment and / or prevention of infections of the skin and / or mucous membranes and / or appendages induced by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S aureus, such as mycoses, eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S. aureus, a mycosis and / or erythema, in particular infant diaper rash, and / or in the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies linked to reactive and / or atopic skin and / or mucous membranes.

[0246] The invention also relates to a method for treating and / or preventing infections of the skin and / or mucous membranes and / or appendages induced by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S aureus, such as mycoses, eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S. aureus, mycosis and / or erythema, in particular diaper rash in infants, and / or a method for preventing and / or treating pharmaceutically, in particular dermatologically, pathologies linked to reactive and / or atopic skin, in a patient in need thereof, comprising the administration of a pharmaceutically or dermatologically effective amount of a dermatological composition according to the invention, to said patient.

[0247] The invention also relates to the use of a dermatological composition according to the invention, for the preparation of an anti-inflammatory composition and / or an antibacterial composition and / or a medicament for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or appendages induced by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S aureus, such as mycoses, eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic microorganism, such as a yeast or a pathogenic bacterium such as S. aureus, a mycosis and / or erythema, in particular infant diaper rash, and / or for the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies linked to reactive and / or atopic skin and / or mucous membranes.

[0248] In an advantageous embodiment, the live probiotic bacteria strain is contained in the dermatological composition, at a concentration per gram of composition ranging from 10 9 colony forming units (CFU) at 10 15 CFU / g, preferably ranging from 10 9 at 10 13 CFU / g.

[0249] The invention will now be illustrated with the aid of the examples below. Other aims, characteristics and advantages of the invention will become clear to those skilled in the art upon reading the explanatory description which refers to examples. These are presented for information purposes only and in no way limit the invention.

[0250] The examples are an integral part of the present invention and any feature appearing new over any prior art from the description taken as a whole, including the examples, is an integral part of the invention in its function and generality.

[0251] So each example has a general scope.

[0252] On the other hand, in the examples, and unless otherwise indicated, the temperature is expressed in degrees Celsius and the pressure is atmospheric pressure.

[0253] EXAMPLES

[0254] Example 1: Preparation of a composition according to the invention

[0255] The isolated Lactobacillus crispatus (CNCM 1-5579) bacteria were inoculated into an MRS culture medium (Man, Rogosa, Sharpe agar), incubated at 37°C anaerobically. The pH was maintained at pH = 6, and the medium was incubated for 24 hours. At the end of incubation, the entire medium including the bacteria was centrifuged, the cell concentrate was recovered and lyophilized in the presence of maltodextrin, for a final quantity of maltodextrin of 50% (w / w) by weight relative to the total weight of the mixture.

[0256] The powder obtained, composed of a mixture of 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin, is dispersed at 0.425% (w / w) in coconut caprylate (Cetiol® C5 marketed by BASF) in sufficient quantity to reach 100% (w / w) of the composition.

[0257] Example 2 Monitoring the viability of live probiotic bacteria in a composition according to the invention

[0258] Protocol:

[0259] The composition according to the invention was obtained according to example 1.

[0260] The tested composition was stored at 4°C (T4°C) and at room temperature (Tambient, i.e., between 18°C ​​and 25°C, especially around 21°C). At the beginning of the study (T0) and at regular time intervals (T1 month, T2 months, T3 months, T6 months, T12 months and T1 month), the composition was taken and spread on MRS agar (Man Sharp Rugosa). The agars were incubated in anaerobic jars at 37°C for 3 days, then the colonies were counted. The results are expressed in CFU (colony forming units) per gram of composition in Table 1 ([Table 1]).

[0261] Results :

[0262] [ Table 1]

[0263] The composition tested according to the invention exhibits good maintenance of the viability of the live bacterial strain thanks to the presence of liposoluble and lipodispersed molecules with a linear chain in sufficient quantity.

[0264] Example 3: comparative studies with the addition of two linear chain molecules according to the invention

[0265] Protocol:

[0266] A composition 1 is made from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin, which is dispersed at 1% (w / w) in a branched-chain ester, here a capric / caprylic triglyceride in sufficient quantity to complete the composition to 100% (w / w). A following composition 2 is made from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin:

[0267] %(w / w) relative to the final composition

[0268] Caprylic / capric triglyceride 39.08

[0269] Coco caprylate / caprate blend 20

[0270] Vegetable oil 20

[0271] Linoleic acid 20

[0272] Tocopherol 0.5

[0273] Phase B: Z. crispatus / maltodextrin mixture in ratio 1:1 0.42

[0274] The ingredients of phase A are mixed together at room temperature, then phase B is added with gentle stirring. Composition 2 contains 40% of liposoluble and lipodispersed linear chain molecules according to the present invention.

[0275] The viability of the probiotic bacteria strain is monitored in the same way as in Example 2 (see [Table 2]).

[0276] Results :

[0277] [Table 2],

[0278] After one day of storage at 4°C in composition 1 comprising a capric / caprylic triglyceride, no more live bacteria are measured. The addition of an amount of 40% by weight relative to the total weight of the composition of liposoluble and lipodispersed molecules with a linear chain according to the present invention makes it possible to restore the viability of the probiotic live bacteria strain.

[0279] Example 4: comparative studies with the addition of three linear chain molecules according to the invention A composition 3 is produced from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin, which is dispersed at 1% (w / w) in a fatty substance composed of a branched fatty chain of alcohol type, here octyldodecanol in a sufficient quantity to complete the composition to 100% (w / w).

[0280] The following composition 4 is produced from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin:

[0281] %(w / w) relative to the final composition dicaprylyl carbonate 11.95 vegetable oil 10 coco caprylate / caprate mixture (Cetiol C5C) 25

[0282] Caprylic / capric triglyceride 20

[0283] Octyldodecanol 25

[0284] Tocopherol 0.5

[0285] Undecane and tridecane mixture (Cetiol® ultimate) 5.00

[0286] Argania spinosa nut vegetable oil (active ingredient) 2.50

[0287] Phase B: Z. crispatus / maltodextrin mixture in a ratio of 1:1 0.05

[0288] The ingredients of phase A are mixed together at room temperature, then phase B is added with gentle stirring. Composition 4 contains 42% (w / w) of liposoluble and lipodispersed linear chain molecules according to the present invention (dicaprylyl carbonate, coco caprylate / caprate and undecane and tridecane mixture).

[0289] The viability of the probiotic bacteria strain is monitored in the same way as in Example 2 (see [Table 3])-

[0290] Results :

[0291] [Table 3]

[0292] After two months of storage at 4°C in composition 3 comprising octyldodecanol, no more live bacteria are measured. The addition of an amount of 42% by weight relative to the total weight of the composition of liposoluble and lipodispersed molecules with a linear chain according to the present invention makes it possible to maintain the viability of the probiotic live bacteria strain.

[0293] Example 5: Comparative studies with the addition of four linear chain molecules according to the invention

[0294] The following composition 5 is produced from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin:

[0295] Phase A: %(w / w) relative to the final composition dicaprylyl carbonate 13 coco caprylate / caprate blend (Cetiol C5C) 13 shea butter 4 coconut glycerides 12

[0296] Octydodecanol 13.65

[0297] Hydrogenated Castor Oil 4

[0298] Behenyl alcohol 8

[0299] Tocopherol 0.5

[0300] Microcrystalline cellulose 20

[0301] Phase B:

[0302] Undecane and tridecane mixture (Cetiol® ultimate) 10.00 Z. crispatus / maltodextrin mixture in ratio 1:1 0.05

[0303] The ingredients of phase A are mixed together by heating to 85°C with stirring. When phase A is homogeneous, phase B is added at 65°C with gentle stirring and then the whole is left to cool to room temperature. Composition 5 contains 44% (w / w) of liposoluble and lipodispersed linear chain molecules according to the present invention (dicaprylyl carbonate, coco caprylate / caprate and undecane and tridecane mixture and behenyl alcohol).

[0304] The viability of the probiotic bacteria strain is monitored in the same way as in example 2 (see [Table 4]).

[0305] Results: [Table 4]

[0306] After two months of storage at 4°C in composition 3 comprising Toctydodecanol, no more live bacteria are measured. The addition of an amount of 44% by weight relative to the total weight of the composition of liposoluble and lipodispersed molecules with a linear chain according to the present invention makes it possible to maintain the viability of the probiotic live bacteria strain.

[0307] Example 6: comparative studies with a content of at least 40% in linear chain molecules according to the invention a) Formulation in a branched chain molecule, squalane.

[0308] A composition is made from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin, added to squalane at 1% by weight relative to the total weight of the composition (squalane+L crispatus / maltodextrin mixture in a 1:1 ratio).

[0309] Squalane is a branched-chain molecule with the formula C30H62.

[0310] The viability of the probiotic bacteria strain is monitored in the same way as in example 2 at 4°C (see

[0311] [Table 5]).

[0312] Results

[0313] [Table 5]

[0314] After two months of storage, the viability of the live bacterial strain decreased by more than 2 log units and at three months, no more live bacteria were measured in the composition. These results allow us to predict that the viability of the live bacterial strain at room temperature would be lost at least as quickly, or even more quickly. b) Formulation in the presence of at least 30% of linear chain molecules according to the invention A following composition 6 is made from the same initial mixture in powder form comprising 50% by weight of the L. crispatus strain and 50% by weight of maltodextrin.

[0315] Phase A: %(w / w) relative to the final composition shea butter 46.45 rapeseed oil 20.00 coco caprylate / caprate blend (Cetiol C5) 20.00 Passiflora incarnata seed oil 5.00 myristyl myristate 3.00 beeswax 2.00

[0316] Squalane 3.00

[0317] Tocopherol 0.5

[0318] Phase B: Z. crispatus / maltodextrin mixture in a ratio of 1:1 0.05

[0319] The ingredients of phase A are mixed together by heating to 75°C with stirring. When phase A is homogeneous, phase B is added at 65°C with gentle stirring and then the mixture is left to cool to room temperature. Composition 6 contains at least 40% (w / w) of straight chain liposoluble and lipodispersed molecules according to the present invention (coco caprylate / caprate at 20%) and other straight chain liposoluble and lipodispersed molecules (rapeseed oil which contains 80% oleic acid, Passiflora incarnata seed oil which contains at least 70% oleic acid, 7% linoleic acid, 1.4% behenic acid, 11% palmitic acid and 5% stearic acid, myristyl myristate, beeswax which contains myricyl palmitate and cerotic acid otherwise known as hexacosanoic acid)

[0320] The viability of the probiotic bacteria strain is monitored in the same way as in Example 2 (see [Table 6]).

[0321] [Table 6]

[0322] After three months of storage at 4°C in composition 6) comprising squalane, no more live bacteria are measured. The addition of an amount of 40% by weight relative to the total weight of the composition of liposoluble and lipodispersed molecules with a linear chain according to the present invention and 10% by weight relative to the total weight of the composition of other liposoluble and lipodispersed molecules with a linear chain makes it possible to maintain the viability of the probiotic live bacteria strain. On the other hand, the presence of more than 40% of liposoluble and lipodispersed molecules with a branched chain (shea butter + squalane) leads to a decrease of 2 log units from 3 months, which reflects a loss of viability at room temperature.

[0323] (original in electronic form)

[0324] (This sheet is not part of the international application nor does it count as a sheet thereof) (original in electronic form)

[0325] (This sheet is not part of the international application nor does it count as a sheet thereof)

[0326] RESERVED FOR THE RECEIVING OFFICE

[0327] FOR INTERNATIONAL OFFICE USE ONLY

Claims

DEMANDS 1. Cosmetic and / or dermatological composition comprising - at least one strain of live probiotic bacteria, - at least one lipodispersible and liposoluble linear-chain molecule selected from dicaprylyl carbonate; coco caprylate, possibly combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear-chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or mixtures thereof, - and possibly one or more other lipodispersible and liposoluble linear chain molecules, in which the total content of lipodispersible and liposoluble linear chain molecules is at least 40% by weight relative to the total weight of the composition.

2. A cosmetic and / or dermatological composition according to the preceding claim, wherein the other lipodispersible and liposoluble linear-chain molecule is selected from: - Alkane molecules with chemical formula C n H 2n+2 where n denotes a value ranging from 6 to 40, - Ester molecules with the chemical formula CH3-C x H 2x -COO- C y H 2y - CH3 in which each of x and y independently designates a value ranging from 5 to 19, - Acidic molecules with the chemical formula CH3- C x H 2x -C(O)OH in which x denotes a value from 5 to 24, preferably from 5 to 21, such as cerotic acid, - Alcohol molecules with the chemical formula CH3-C x H 2x -OH in which x denotes a value from 5 to 21, and any of their mixtures.

3. Cosmetic and / or dermatological composition according to one of the preceding claims, wherein the lipodispersible and liposoluble linear-chain molecule selected from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear-chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or mixtures thereof, is present at a content of at least 8%, preferably at least 10%, and even more preferably at least 15%, by weight relative to the total weight of the composition.

4. Cosmetic and / or dermatological composition according to one of the preceding claims, wherein the lipodispersible and liposoluble linear chain molecule is dicaprylyl carbonate.

5. A cosmetic and / or dermatological composition according to any one of the preceding claims, wherein the selected linear-chain lipodispersible and liposoluble molecule is coco caprylate, optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate.

6. Cosmetic and / or dermatological composition according to any one of the preceding claims, wherein the selected linear-chain lipodispersible and liposoluble molecule is dicaprylyl carbonate.

7. Cosmetic and / or dermatological composition according to any one of the preceding claims, wherein the selected linear-chain lipodispersible and liposoluble molecule is undecane and / or tridecane.

8. Cosmetic and / or dermatological composition according to any one of the preceding claims, wherein the selected linear-chain lipodispersible and liposoluble molecule is linoleic acid and / or oleic acid, and / or isostearyl linoleate and / or oleic alcohol, preferably linoleic acid.

9. Cosmetic and / or dermatological composition according to any one of the preceding claims, wherein the selected linear-chain lipodispersible and liposoluble molecule is behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters, preferably behenyl alcohol.

10. Cosmetic and / or dermatological composition according to any one of the preceding claims, wherein the lipodispersible and liposoluble linear-chain molecule selected from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear-chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or mixtures thereof is present at a content of at least 40%, preferably at least 50%, and again preferably at least 60%, by weight relative to the total weight of the composition.

11. Composition according to any one of the preceding claims wherein the composition comprises at least two, preferably three or four, linear-chain lipodispersible and liposoluble molecules selected from dicaprylyl carbonate; coco caprylate optionally combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear-chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters.

12. Composition according to any one of the preceding claims wherein the composition further comprises a branched-chain liposoluble and lipodispersible molecule selected from octyl dodecanol, propylheptyl caprylate, a mixture of caprylic and capric triglyceride, hydrogenated castor oil, shea butter, coconut oil and / or coconut glycerides.

13. Composition according to any one of the preceding claims wherein the probiotic live bacterial strain is selected from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus, and mixtures thereof.

14. Composition according to any one of the preceding claims wherein the live bacterial strain is formulated from powder obtained by lyophilization on a maltodextrin support, preferably from 10% to 80% by weight relative to the total weight of powder, preferably from 30% to 70%, more preferably from 40% to 60%, by weight relative to the total weight of powder.

15. Composition according to any one of the preceding claims, wherein the live bacterial strain is at a concentration of 10 3 at 10 15 CFU (colony forming unit) per gram of composition.

16. Composition according to any one of the preceding claims wherein the live bacterial strain is at a content of 0.01 to 3% by weight, relative to the total weight of the composition.

17. Composition according to any one of the preceding claims, wherein the water activity (Aw) in the composition is less than 0.

6.

18. Composition according to any one of the preceding claims, characterized in that it is in the form of a suspension or solution, oily, an oily cream or gel, a milk, a water-in-oil or multiple or silicone emulsion, a mask, a serum, a lotion, a solid soap, a solid shampoo, solid foaming products, a dermatological bar, an ointment, a mousse, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of makeup powders, a stick or a lozenge.

19. Non-therapeutic use of a cosmetic composition as defined in any of the preceding claims, to prevent and / or reduce unsightly and / or uncomfortable manifestations of healthy skin, healthy hair and / or mucous membranes, in particular of sensitive or sensitized skin, hair and / or mucous membranes, fragile or weakened skin, hair and / or mucous membranes, and / or dry and / or atopic-prone skin, hair and / or mucous membranes.

20. Non-therapeutic use of a cosmetic composition as defined in any of the preceding claims, as a moisturizing and / or soothing agent for healthy skin, healthy hair and nails and / or healthy mucous membranes.

21. Non-therapeutic use of the cosmetic composition as defined according to any one of the preceding claims by topical application, preferably on an area of ​​healthy skin, mucous membrane and / or hair selected from the legs; feet; armpits; hands; thighs; hips; buttocks; waist; crotch; groin; belly; décolleté; neck; arms; torso; back; face; scalp; hair; nails; and / or labial mucosa, advantageously the armpits, décolleté, hair, nails, labial mucosa and / or face, further advantageously the face.

22. Dermatological composition as defined in any one of claims 1 to 18, for use as an anti-inflammatory agent, antibacterial agent and / or in the treatment and / or prevention of skin and / or mucous membrane and / or hair infections induced by a pathogenic microorganism, such as a yeast or pathogenic bacterium such as S. aureus, such as mycoses, eczema, seborrheic or atopic dermatitis, acne, and cutaneous or mucosal inflammation caused by a pathogenic microorganism, such as a yeast or pathogenic bacterium such as S. aureus, mycosis and / or erythema, in particular diaper rash, and / or in the prevention and / or pharmaceutical treatment, in particular dermatological treatment, of pathologies related to reactive and / or atopic skin and / or mucous membranes.

23. Use of at least one linear-chain lipodispersible and liposoluble molecule selected from dicaprylyl carbonate; coco caprylate possibly combined with coco caprate, preferably a mixture of coco caprylate and coco caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or their linear-chain esters and / or oleic alcohol; behenyl alcohol and / or its acid derivatives and esters, in particular behenic acid, or docosanoate or behenate esters; and / or mixtures thereof, and possibly one or more other linear-chain lipodispersible and liposoluble molecules, to maintain the viability of a live probiotic bacterial strain, wherein the total weight sum of linear-chain lipodispersible and liposoluble molecules is at least 40% by weight relative to the total weight of a cosmetic or dermatological composition.

24. Use according to the preceding claim characterized in that the composition is as described in any one of claims 1 to 18.

Images